The CNN report sets sustained weight loss as a headline question. What matters isn't just the headline figure but how the longer trial treated plateaus, dropouts, and the gap between completers and the overall population.

What side effects emerged over years of follow-up?

Gastrointestinal symptoms — nausea, vomiting, diarrhea, constipation — dominate Wegovy's safety profile across every published trial. Most are mild to moderate and tend to fade with time.

A multi-year follow-up tests different questions: do GI events persist across years? Do rarer but more serious concerns — gallbladder disease, pancreatitis, suicidal thoughts, intestinal blockage — emerge at rates shorter trials missed? The CNN framing suggests the report engages with these directly.

Did the trial show heart protection?

This is the highest-stakes question. Earlier large trials of semaglutide in people with type 2 diabetes showed cardiovascular benefit. The open question for Wegovy is whether that benefit extends to people with obesity but without diabetes.

Positive heart data reshapes who the drug is for and which insurers pay. The CNN report appears to address this, but the actual hazard ratios, confidence intervals, and absolute risk reductions need the original source.

What does this change for someone considering Wegovy?

Right now, the CNN headline is a roadmap, not a destination. The numbers that matter — average weight loss in the long-term cohort, side effect persistence rates, cardiovascular event reductions — sit in the full CNN piece and in the underlying peer-reviewed publication.

Practical guidance: read the original CNN report. Then wait for the peer-reviewed paper. Talk to a clinician about how the findings apply to your situation. Be skeptical of any specific number quoted out of context — including in this article.

What couldn't this article verify?

This rewrite draws on the CNN report's headline and stated scope. Specific figures from the trial — weight loss percentages, side effect rates, hazard ratios — were not in the materials received. Treat any number that lacks a clear source the way a careful reader treats any unsourced claim: with caution.